Mark Krul

Mark Krul is the Chief Scientific Officer at Oncode Accelerator and serves as a Board Member at MIMETAS, Cristal Therapeutics, Macrophage Pharma Ltd., and Inthera Bioscience AG. Mark is the Founder and Director of Aglaia Oncology Fund II. With a Ph.D. in Medical Biology from Utrecht University, Mark has a wealth of experience in drug development and research management in the field of oncology.